|Bid||13.07 x 3200|
|Ask||13.25 x 2200|
|Day's Range||12.81 - 13.70|
|52 Week Range||3.01 - 22.39|
|Beta (3Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 10, 2018 - Dec 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.30|
In this daily bar chart of ARWR, below, we can see some strong price performance from December with prices rallying from $4 to touch $22 - impressive. The daily On-Balance-Volume (OBV) line shows an interesting rise from November to September. In this weekly bar chart of ARWR, below, we can see a parabolic rally from just $2 back in 2017 to $22 - one heck of a return.
Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
— Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics
Arrowhead Pharmaceuticals Inc. will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease being held on November 9-13, 2018, in San Francisco.
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.
When the market opened in 2018, Arrowhead Pharmaceuticals stock was selling at $3.69. Cantor Fitzgerald has raised its target price for Arrowhead Pharmaceuticals to $24 from $18. In July, Chardan Capital raised its price target to $24.50 from $17.50.
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B. It also follows the first U.S. approval for an RNAi drug - Alnylam Pharmaceuticals' (ALNY.O) Onpattro - in August that affirmed the gene-silencing class of drugs as a new frontier in the field of medicine.
Arrowhead Pharmaceuticals touted a deal with Johnson & Johnson with a price tag more than the double the company’s market value, but the actual figure may be far smaller.
Investing.com - Stocks in focus in pre-market trade Thursday:· Barnes & Noble (NYSE:BKS) stock jumped 21.25% as of 8:20 AM ET (12:20 GMT) after the struggling bookstore chain announced it was exploring a takeover.· Tilray (NASDAQ:TLRY) stock slumped 3.72% after the company announced it was offering $400 million worth of convertible senior notes to be used for working capital, acquisitions and to repay a $9.1 million mortgage on a production facility in British Columbia.· Apple (NASDAQ:AAPL) and Amazon. ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) develops medicines to treat intractable diseases. Arrowhead announced entrance into a $3.7-billion license and collaboration agreement with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ). This funding will consist of $250 million upon closing, as well as an upfront payment from Janssen and a $75 million equity investment from Johnson & Johnson Innovation.
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide license for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B.
Arrowhead Pharmaceutics Inc. stock surged 19% in premarket trade Thursday, after the company said it has entered a $3.7 billion license and cooperation agreement with Janssen Pharmaceuticals Inc. to develop and commercialize its ARO-HBV treatment for chronic hepatitis B. As part of the deal, Arrowhead will receive $175 million upon close and Janssen parent Johnson & Johnson Innovation JJDC Inc., a unit of Johnson & Johnson , will buy a $75 million stake priced at $23 a share of Arrowhead common stock. Arrowhead will be eligible to receive up to $1.6 billion in milestone payments and another roughly $1.9 billion in option and milestone payments for reaching three additional targets. The company will also be eligible for tiered royalties on product sales. Janssen will have an exclusive license on the ARO-HBV program, a subcutaneously administered RNAi therapeutic candidate aimed at treating hepatitis B. The deal is expected to close in the fourth quarter. Arrowhead shares have gained 404% in 2018, while the S&P 500 has gained 9%.
- Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize ARO-HBV.
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City. The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU Langone Medical Center) who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia. Arrowhead's management team will provide an overview of the company’s pipeline of RNAi-based therapeutics.